Trubion Pharmaceuticals, a biopharmaceutical company developing drugs to treat rheumatoid arthritis and systemic lupus erythematosus, announced the terms for its IPO on Monday. The Seattle-based company plans to offer 4 million shares at $13-$15 per share. The deal has a proposed market cap of $254 million. Morgan Stanley, Banc of America, Pacific Growth Equities and Lazard Capital Markets are set to manage the deal. Timing has yet to be announced.
